23 trends tracked about this subject — the full history, oldest to newest below.
Experimental drug retatrutide cut knee osteoarthritis pain by half for nearly 70% of patients across two clinical trials while also reducing body weight.
An experimental weight-loss drug significantly eased knee pain in two major new trials, according to coverage from Everyday Health.
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
A new study found that 54% of younger adults with early-onset type 2 diabetes achieved remission after six months of an intensive diet and exercise program.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
An experimental weight-loss drug named Retatrutide is making news for potentially improving sleep apnea symptoms.
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
An investigational triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in late-stage clinical trials.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Unapproved weight loss drug retatrutide faces a booming black market linked to multiple reported deaths and severe side effects.
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Lilly positions its retatrutide drug combo for a next-generation obesity battle following full phase 3 study results.
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly targets the illicit market for its unapproved obesity drug retatrutide through new legal actions.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.